IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
Members of IMV’s leadership will share data via an oral presentation as well as a poster session. Details are as follows:
|‘Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV Small Hydrophobic protein’|
|Oral Presentation:||Oral Abstracts, Session 3|
|Poster Presentation:||Abstract #105|
|Location:||Salon F & G|
RespiDART is a new addition to the DART series of healthcare conferences and is focused on drug development challenges and advances for respiratory virus threats to human health. These viruses include long-standing threats such as RSV and influenza, as well as recent outbreaks of MERS-coV, parainfluenza virus, and metapneumovirus. This meeting will focus on advances in therapeutics, vaccinology, virus/host interactions and enzymology, and new study models in development. By bringing together world leaders and key opinion holders, RespiDART 2018 aims to address the latest challenges in vaccine and drug development against respiratory viruses.
Contacts for IMV:
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com
Source: IMV Inc.